<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045001</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-IIL-2020-148</org_study_id>
    <nct_id>NCT05045001</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases</brief_title>
  <official_title>Observational Retrospective Studies on Single Nucleotide Variants (SNPs) on the Interleukin-6 Receptor (IL6R) and Their Influence on the Response to Treatment and Safety in Patients With Specific Rheumatic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tocilizumab and Sarilumab are first-line biological disease-modifying anti-rheumatic drug&#xD;
      (bDMARD) which inhibits Interleukin 6 (IL-6) pathway through blockade of its receptor on the&#xD;
      treatment of Rheumatoid Arthritis and other rheumatic diseases as Giant Cell Arteritis,&#xD;
      Still's disease and Idiopathic Juvenile Arthritis. At present, there is a lack of evidence to&#xD;
      recommend the treatment of one bDMARD over another. Seeking for genetic biomarkers to predict&#xD;
      response to treatment could be key towards a personalized treatment strategy in rheumatology.&#xD;
&#xD;
      The investigators aime to evaluate whether functional single nucleotide polymorphisms (SNPs)&#xD;
      in the IL6R gene could predict response and/or toxicity in patients with rheumatic diseases&#xD;
      treated with anti-IL-6 receptor drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DAS28-C-reactive Protein (CRP) change</measure>
    <time_frame>at 6 months</time_frame>
    <description>Activity measure for patients with Rheumatoid Arthritis (RA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>During treatment with anti-IL6R drugs</time_frame>
    <description>Known adverse events during treatment with anti-IL6R drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CRP change</measure>
    <time_frame>6 months</time_frame>
    <description>Acute phase reactant reduction in the other diseases different of RA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte sedimentation rate (ESR) change</measure>
    <time_frame>6 months</time_frame>
    <description>Acute phase reactant reduction in the other diseases different of RA.</description>
  </primary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Idiopathic Juvenile Arthritis</condition>
  <condition>Giant Cell Arteritis</condition>
  <condition>Still Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples will be collected and stored following the appropriate national laws of Spain (&#xD;
      Ley de Investigación Biomédica 14/2007) regarding the use of human biological samples in&#xD;
      biomedical investigation. Collection and storage approved by the organization's ethic&#xD;
      committee.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients being followed-up in the Hospital de la Santa Creu i Sant Pau, diagnosed of&#xD;
        Rheumatoid Arthritis, Idiopathic Juvenile Arthritis, Still disease or Giant Cell Arteritis&#xD;
        treated with anti-IL6R drugs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All the patients diagnosed with Rheumatoid Arthritis by the American College of&#xD;
             Rheumatology (ACR) 2010 criteria, with Giant Cell Arteritis by International League of&#xD;
             Associations for Rheumatology (ILAR) criteria, with Still disease by classification&#xD;
             criteria (Yamaguchi et al.) and with Idiopathic Juvenile Arthritis by ACR 1990&#xD;
             criteria. All of them treated with anti-IL-6R monoclonal antibodies in the last 5&#xD;
             years and with active follow-up in Hospital de la Santa Creu i Sant Pau.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years at recruitment&#xD;
&#xD;
          -  Another rheumatic disease different of the ones in the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Moya, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Sainz</last_name>
    <phone>679743541</phone>
    <phone_ext>+34</phone_ext>
    <email>lsainz@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Sainz</last_name>
      <phone>679743541</phone>
      <phone_ext>+34</phone_ext>
      <email>lsainz@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

